The development of monoclonal antibody (MAb) therapy has revolutionized our approach to cancer treatment. Several MAbs are now approved for clinical use and are very effective against some types of cancer. Unfortunately, many cancers are resistant to treatment with MAbs alone, but can be killed when a cytotoxic agent is attached to the antibody. Immunoconjugates of this kind are made by attaching chemotherapy drugs, radioisotopes, enzymes or toxins to the antibody. This Perspective focuses on the use of toxins.
Immunotoxins derive their potency from the toxin and their specificity from the antibody or antibody fragment to which they are attached. We will describe the properties of the commonly used toxins, the principles of immunotoxin design and production, and results from recent clinical trials. Other recent reviews provide additional perpectives on the immunotoxin field [1] [2] [3] [4] [5] .
Toxins used to make immunotoxins
Clinical trials of recombinant immunotoxins use one of two bacterial toxins. Both Pseudomonas aeruginosa exotoxin A (PE, 613 amino acids) and diphtheria toxin (DT, 580 amino acids) are produced as single polypeptide chains, each of which has three functional domains. Domain Ia, which is located at the N terminus, is the cell-binding domain of PE, domain II has translocation activity and domain III, which is located at the C terminus, catalyses the adenosine diphosphate (ADP)-ribosylation and inactivation of elongation factor 2 (EF2), which leads to the inhibition of protein synthesis and cell death (FIG. 1) . A minor domain called Ib has no known function and is usually deleted. PE binds the α-2-macroglobulin receptor (also known as LRP1), which is expressed in many cell types, and is then internalized through clathrin-coated pits into the endocytic compartment where several processing steps occur (FIG. 1) .
Following proteolytic cleavage between amino acids 279 and 280 and reduction of the disulphide bond that connects residues 265 and 287, a 37 kDa fragment (amino acids 280-612) that is derived from the C terminus is transported to the endoplasmic reticulum and is then translocated to the cytosol, where it encounters and inactivates EF2. PE-based immunotoxins are currently produced by removing domain Ia (amino acids 1-253) and a large portion of domain Ib, and replacing domain Ia with a targeting moiety such as the Fv portion of an antibody or a growth factor (FIGS 2, 3) . This modified form of PE is known as PE38 to reflect its molecular weight. For DT, the ADP-ribosylation activity occurs at the N terminus and its cell-binding domain is at the C terminus (amino acids 482-539). The receptor for DT is the heparinbinding epidermal growth factor (EGF)-like precursor 6 . After cell binding, DT undergoes internalization, proteolytic activation and disulphide bond reduction, similar to PE, but translocation to the cytosol occurs directly from the acidic endocytic compartment 7 . Chimeric toxin molecules are made by replacing the cell-binding domain at the C terminus of DT with a growth factor or the Fv fragment of an antibody (FIG. 4) .
Early immunotoxin molecules were often constructed using plant toxins. Ricin and similar toxins that inhibit protein synthesis by attacking ribosomal RNA were chemically attached to antibody molecules. For various reasons that are related to inefficient cellular processing and release of the toxin from the Fv fragment, the conversion from chemical conjugation methods to recombinant expression has not favoured plant toxins. In addition, the use of ricin-A-chain immunotoxins has been associated with vascular damage. Recent efforts have focused on the development of genetically altered ricin-A-chains with more favourable properties 8 .
The development of immunotoxins
First-generation immunotoxins that were prepared by chemically conjugating whole toxins to antibodies were often not effective in animal models because the toxin also killed normal cells. The removal of the cell-binding domain from the toxin and attachment of this modified toxin to various antibodies produced immunotoxins that were much better tolerated by animals. Several of these second-generation immunotoxins have been evaluated in phase I trials in cancer patients. Some anti-tumour activity has been observed but these agents are costly to produce, chemically heterogeneous and, because of their large size, penetrate slowly into bulky tumours. Third-generation immunotoxins overcome these difficulties. Using recombinant DNA techniques and the principles of protein engineering, immunotoxins are now designed to contain only the elements required to recognize and kill the tumour cells. This is accomplished by replacing the cell-binding domain of the Abstract | Rationally designed anticancer agents that target cell-surface antigens or receptors represent a promising approach for treating cancer patients. However, antibodies that bind these targets are often, by themselves, non-cytotoxic. By attaching potent toxins we can dramatically improve the clinical utility of some anti-tumour antibodies. Here we describe the construction and clinical utility of several recombinant immunotoxins; each of which is composed of antibody Fv fragments fused to powerful bacterial toxins. Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy. (FIG. 2) . These recombinant chimeric proteins are produced in Escherichia coli. Large amounts of protein can be made economically from this source. The heavy and light chain portions of the antibodies that are used to make these immunotoxins are either linked by a peptide linker (scFv) or the Fv is stabilized by a disulphide bond (dsFv). Another way to target toxins to cells is to replace the cell-binding domain with a growth factor or cytokine. Examples include interleukin 2 (IL2), transforming growthfactor α (TGFα), granulocyte-macrophage colony stimulating factor (GMCSF) and IL13.
The attraction of using an antibody-toxin or a cytokine-toxin fusion protein to kill cancer cells is the high potency of the toxin. One disadvantage is that toxins are foreign proteins, and patients with solid tumours and normal immune systems develop neutralizing antibodies, which prevents retreatment. Fortunately, neutralizing antibody formation is infrequent in patients with lymphomas and leukaemias, because the diseases are frequently immunosuppressive and because the chemotherapy these patients receive also damages the immune system. Toxicity associated with immunotoxins can be either nonspecific or targeted. An example of nonspecific toxicity is vascular leak syndrome (VLS), in which there is fluid leakage from capillaries, a fall in serum albumin, fluid retention, oedema and weight gain. This toxicity, owing to endothelial cell damage caused by the high concentration of immunotoxins, can usually be managed by adequate hydration, although severe vascular collapse has been observed at high doses with ricin-based immunotoxins.
The second type of toxicity is caused by targeting the toxin to normal tissues that contain the same target antigen as the cancer cell. This is not a problem if immunotoxins are targeted to antigens on B-or T-cell malignancies, because normal B and T cells can be regenerated from antigen-negative stem cells. But it is a serious problem if solid tumours are targeted, as the antigen can be present on vital organs such as the kidneys, the liver or nerve cells, and the immunotoxin will kill normal cells in these tissues [9] [10] [11] . It is essential that the target antigen be restricted in its expression to non-essential normal cells.
Clinical trials of immuntoxins
This section summarizes recent and ongoing clinical trials of various immunotoxins in both haematological malignancies and solid tumours (TABLE 1) . Because different immunotoxins can target the same antigen on cancer cells, we have summarized these clinical trials on the basis of the antigens that are being targeted.
Immunotoxins targeting the IL2 receptor. Murphy and colleagues have used recombinant DNA techniques to target DT to cells that express the high affinity IL2 receptor (IL2R) by replacing the cell-binding domain of DT with IL2 (FIG. 4) . DAB389IL2 (denileukin diftitox or Ontak) is approved for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL). Denileukin diftitox produced response rates of 30%, which includes 10% complete remissions (CRs) [12] [13] [14] . Most patients had objective improvement in skin lesions. Common toxicities included fatigue, VLS with hypotension and low albumin, transaminase elevations and rashes. VLS can be controlled with steroid prophylaxis 13, 15, 16 . The retinoid bexarotene increases IL2 expression in CTCL, and with denileukin diftitox produced 3 CRs and 3 partial responses (PRs) in 12 patients with CTCL 17 . Denileukin diftitox produced response rates of 33% and 25% in chronic lymphocytic leukaemia (CLL) 18 and non-Hodgkin lymphoma (NHL) 19 . In addition to its use in the treatment of cancers that express IL2R, denileukin diftitox is being studied to eliminate regulatory T cells that express CD25 to increase the anti-tumour activity of cancer vaccines 20 .
Clinical trials of anti-CD25 immunotoxins.
LMB-2, which targets the α subunit of IL2R, contains the Fv of the anti-CD25 MAb anti-tac 21, 22 fused to the N terminus of PE38 (FIGS 2,3). LMB-2 was given to patients with chemotherapy-resistant leukaemia, lymphoma and Hodgkin disease (HD) in a phase I trial. In this trial there were 7 PRs and 1 CR in the 20 patients who received a total dose greater than 60 µg per kg per cycle. The response rate in hairy-cell leukaemia (HCL) was 100%, with 1 CR and 3 PRs 23 , and patients with CLL, adult T-cell leukaemia (ATL), CTCL and HD had PRs 24 . Dose-limiting toxicity PE38 is a truncated portion of Pseudomonas aeruginosa exotoxin A (PE) that lacks domain Ia. BL22 binds to surface CD22 and then enters the cell through clathrin-coated pits. In the endocytic compartment PE38 is cleaved into two fragments. The C-terminal fragment, which is composed of domain III and a portion of domain II, is transported to the endoplasmic reticulum (ER), presumably through the REDL sequence (REDL functions as a KDEL ER-targeting motif sequence for ER retrieval). From the ER the toxin translocates to the cytosol and adenosine diphosphate (ADP)-ribosylates elongation factor 2 (EF2). This modification causes the inhibition of protein synthesis and leads to cell death. occurred at 63 µg per kg, included reversible cardiomyopathy or transaminase elevations, and was associated with a fever that was consistent with cytokine release 25, 26 . Antibodies that neutralized LMB-2 and prevented retreatment developed in 6 of 35 patients, although none of the 12 CLL patients made neutralizing antibodies. Phase II trials are currently underway in patients with CLL or CTCL. Patients with HCL are now being treated with the anti-CD22 recombinant immunotoxin BL22 (see below).
The anti-CD25 MAb RFT5 and the anti-CD30 MAb Ki-4, which is attached to a deglycosylated ricin-A-chain known as dgA, have both been tested in a phase I and II setting in patients with HD and significant clinical activity has been observed [27] [28] [29] [30] [31] .
Targeting CD22 for treatment of HCL and other haematological cancers. To target CD22, which is expressed in B-cell leukaemias and lymphomas, the variable domains of a MAb to CD22 (RFB4) were cloned and used to make a disulphidelinked recombinant immunotoxin RFB4(dsFv)-PE38 or BL22 (FIG. 1) . BL22 was found to be cytotoxic to cell lines that express CD22 and causes the complete regression of CD22-positive tumours in mice 32, 33 . In a phase I trial, BL22 was given to 46 patients with various B-cell malignancies: HCL, CLL and some B-cell lymphomas. All patients were drug resistant before they entered the trial, and patients with HCL had received 1-6 separate courses of cladribine and other standard therapies. A total of 265 cycles of BL22 were given, which totalled up to 33 cycles per patient. In HCL 34 , 61% CRs and 19% PRs were achieved in 31 patients 35 . All 25 responders benefited clinically after one cycle of treatment. Neutralizing antibodies developed in 11 out of 46 patients, all with HCL, and only in 1 patient after 1 cycle. Mild VLS and transaminase elevations were not dose limiting. Four HCL patients (12%) in the phase I trial developed a reversible haemolytic uremic syndrome during the second or third cycle, which was successfully treated with plasmapheresis. All of these patients responded well to BL22. The maximum tolerated dose (MTD) was established as 40 µg per kg intravenously every 2 days × 3 for cycle 1, with no serious toxicity observed in any of the treated patients. The median duration for CR was 36 months, and 8 remained in CR at 45 months. A higher percentage of patients (73% of 30 patients) achieved haematological remission, which lasted a median of 37 months. BL22 is the first agent that has been reported to induce a high rate of CRs in HCL patients that have resistance to purine analogues. Moreover, the phase I response rates (61% CR, 81% overall response) that were reported in the 31 patients with HCL that were tested were higher than those of any other targeted toxin, including the approved agent denileukin diftitox for CTCL (11% CR, 32% overall response in 106 phase I and II patients). Activity from BL22 was also observed in CLL, which included a durable haematological response that was maintained for nearly 5 years in one patient receiving 33 cycles of BL22. BL22 is currently undergoing phase II testing in HCL and phase I testing in both CLL and in paediatric acute lymphoblastic leukaemia (ALL).
Immunotoxins targeting the GMCSF receptor. DT-GMCSF (DTGM) is a recombinant toxin that targets the GMCSF receptor (GMCSFR) that is present on acute myeloid leukaemia (AML) cells [36] [37] [38] . DTGM induced 1 CR and 2 PRs in 31 chemo-resistant patients with AML 39 . Unfortunately, the further development of this agent has been complicated by liver toxicity, which has been attributed to targeting GMCSFR expressed on KÜpffer cells with subsequent damage to hepatocytes 26, 39, 40 . An alternate approach to treat patients with AML is to target the IL3R using the recombinant toxin DT388-IL3 because this chimeric protein does not target macrophages or KÜpffer cells 41, 42 .
Immunotoxins targeting the Lewis Y antigen for treatment of epithelial cancers. The Lewis Y antigen has been found to be highly expressed in many epithelial tumours 43 . The first clinical activity of PE-based immunotoxins was observed in a phase I trial in which MAb B3 was chemically attached to PE38 (FIG. 2) . This immunotoxin, which is named LMB-1, produced a PR in a patient with colon cancer and a CR in a patient with breast cancer 44 . Dose-limiting toxicity was ascribed to endothelial damage because small amounts of the Lewis Y antigen are present on endothelial cells 45 . Several recombinant immunotoxins that target the Lewis Y antigen have also been tested in the clinic. B3(Fv)-PE38 (LMB-7) was produced by fusing the Fv of the MAb B3 to the N terminus of PE38. In a phase I clinical trial of LMB-7 two significant toxicities were observed. The first toxicity was a targeted toxicity: severe gastritis caused by the killing of normal cells that expressed Lewis Y antigen in the stomach. This toxicity was prevented by blocking acid secretion with the proton pump inhibitor Omeprazole accompanied by antacids. At higher dose levels renal toxicity developed and was dose limiting. This toxicity was probably because of small amounts of Lewis Y present on some tubular cells in the kidney 43 . B3(dsFv)-PE38 or LMB-9, which is a stable disulphide version of LMB-7, was also tested in a phase I trial. In this trial, which used Omeprazole to prevent stomach toxicity, renal toxicity was also dose limiting (I.P., R.H, D.J.F and R.J.K, Omeprazole was not used with this trial, and the dose-limiting toxicity was gastrointestinal (nausea, vomiting and diarrhoea). Clinical activity with immunotoxins that target Lewis Y has been limited, which is in part due to the low affinity of the immunotoxin for this carbohydrate antigen, and the presence of this antigen on cells of the kidney.
Immunotoxins targeting mesotheliomas, ovarian and pancreatic cancers.
Mesothelin is a differentiation antigen that is expressed on the cell membrane of normal mesothelial cells, and is highly expressed on several types of cancer, such as mesothelioma, ovarian and pancreatic cancer [47] [48] [49] . An immunotoxin (SS1P) with a high affinity for mesothelin has been produced by a combination of antibody phage display and Fv mutagenesis 50, 51 . Because this immunotoxin produced CR of mesothelin-bearing tumours in mice and was well tolerated by monkeys whose cells bind SS1P, two phase I clinical trials were initiated at the US National Cancer Institute. In one trial, which has just been completed, SS1P was given by continuous infusion over 10 days 52 . Continuous infusion was tested as an approach to increase tumour uptake. In the other trial, SS1P was given by 30 minute infusion every 2 days for 3-6 doses 53 . The significant dose-limiting toxicity in both trials was pleuritis ascribed to the targeted killing of normal mesothelial cells in the pleura. VLS characterized by weight gain and a fall in serum albumin also occurred, but was not dose limiting 53 . Minor but significant anti-tumour responses were observed after either method of administration, both by computerized tomography and positron emission tomography. The formation of antibodies that neutralized SS1P occurred in over 70% of patients and prevented further treatment cycles. Nevertheless, there was sufficient anti-tumour activity after only one cycle of SS1P to justify a phase II trial. In the phase II trial that is currently being planned, patients with mesothelioma will receive a combination of SS1P and gemcitabine, because this combination is very effective in an animal model (I.P., R.H, D.J.F and R.J.K, unpublished data).
Immunotoxins targeting IL4, IL13 and epidermal growth factor receptors. The term 'immunotoxin' has been extended to include proteins where cytokines are fused to toxins. The efficacy of denileukin diftitox in some leukaemias and lymphomas has already been described. Truncated PE has been fused to several cytokines and growth factors. These include TGFα-PE38 (which targets cells that express epidermal growth factor receptors (EGFR)), IL4(38-37)-PE38KDEL and IL13-PE38QQR. These variants of PE38 share the same cytotoxic activity with the exception of PE38KDEL, for which increased cytotoxic activity has often been noted. The receptors for these cytokines are present on many normal cells so that systemic therapy results in unacceptable toxic side effects. For example, in a phase I trial of IL4(38-37)-PE38KDEL in patients with advanced solid tumours that expressed IL4R, the dose-limiting toxicity was liver damage and no objective responses were observed 54 . These agents are better suited for local therapy, and 3 of these agents that target the EGF, IL4 and IL13 receptors have been evaluated for the therapy of glioblastoma. During treatment, the proteins are slowly infused into or next to the brain tumour by continuous infusion over many hours. This technique of enhancedconvection delivery was initially developed for the administration of a conjugate of transferrin and DT into brain tumours 55 . Phase I and II trials of IL4(38-37)-PE38KDEL showed a few CRs and PRs, but the associated toxicity was unacceptable and development was abandoned 56, 57 . By contrast, both TGFα-PE38 and IL13-PE38QQR are much better tolerated and have shown CRs in some patients during phase I and phase II trials [58] [59] [60] [61] . Their development is being actively pursued.
Improving affinity and activity
The importance of affinity in immunotoxin activity was comprehensively shown in a study in which many different antibodies to CD30 were produced and used to make immunotoxins 62 . A statistically significant correlation of affinity with cytotoxic activity was observed.
Analyses of cells from patients revealed that patients with HCL have 5,000-100,000 CD22 sites per cell and are sensitive to BL22 (inhibitory concentration 50% (IC 50 ) <10 ng ml -1 ). By contrast, cells from CLL patients have only 300-3,000 sites per cell and are much less sensitive to BL22 (IC 50 usually >100 ng ml -1 ). To make a more active immunotoxin we used a combination of antibody phage display and mutagenesis of complementary determining regions (CDRs) to increase the affinity of the Fv. The replacement of amino acids SSY by THW in the CDR3 of the heavy chain of the Fv of BL22 produced a mutant immunotoxin with a 10-fold increase in affinity for CD22 and a 10-100-fold increase in potency against malignant CLL cells from patients 63 . This new immunotoxin, HA22, is currently being produced for phase I clinical testing in CLL, NHL, HCL and ALL.
Vitetta and colleagues have used mutagenesis to improve the properties of ricin-based immunotoxins by mutating the toxin so that it has diminished toxicity to endothelial cells 8, 64, 65 .
Decreasing immunotoxin immunogenicity
Clinical responses to immunotoxins have mainly been observed in haematological malignancies and not solid tumours. One reason for this is that cancer cells located in the blood, bone marrow and spleen are readily accessible to the immunotoxin, whereas ; this approach has been successful in reducing or eliminating the immunogenicity of adenosine deaminase and asparaginase 67 .
Summary
The finding that immunotoxins that target CD22 and CD25 cause reproducible tumour regressions and even complete remissions in many phase I patients with haematological malignancies establishes that these agents can have a useful role in cancer treatment. These results need to be extended to other tumours and particularly solid tumours. One promising target is the mesothelin protein that is expressed on ovarian cancers and on mesotheliomas. Another barrier that needs to be overcome is the poor uptake of therapeutic proteins by solid tumours. This might be achieved by combining immunotoxin therapy with cytotoxic agents that damage blood vessels and diminish the high interstitial pressure within tumours that slows the entry of therapeutic proteins. Finally, the toxin portion of the immunotoxin needs to be made less immunogenic so that neutralizing antibodies do not develop and more treatment cycles can be given. Useful approaches could include identifying and removing T-or B-cell epitopes, modifying the protein with high molecular weight polyethylene glycol or treating patients with immunosuppressive agents.
